United States Antimony Corporation (UAMY) is the only operating US antimony smelter, scaling into a vertically-integrated Western antimony platform via three feedstock streams: Thompson Falls (Montana), a 49/51 hydromet JV with First Majestic Silver (USAS), and a 10% strategic stake in Larvotto Resources (ASX:LRV). The Q1 2026 10-Q filed May 14 contained one disclosure the market hasn't priced.

What the filing says

MD&A liquidity section: "The Company has made formal applications in 2026 to several governmental agencies of $274 million." Public consensus knows about $27M (DoW DPA Title III, awarded March 5, 2026). The disclosed pipeline is 10x that. Note 12 confirms the JV hydromet DoW grant application is formally filed — previously listed as "anticipated" in UAMY's Feb 2026 investor presentation. Of the $27M existing grant: $12.8M approved across 3 milestones as of March 31, cash received April. Thompson Falls expansion ≈$16M of ≈$32M capex incurred, guided to Q2 2026 completion.

Q1 cash collapsed $30.5M → $3.2M, but the post-period $48.6M ATM at $11.57/share and the $12.8M grant inflow brought pro-forma liquidity to ≈$64M. No going concern language; long-term debt $161K. CFO Richard Isaak commenced "personal leave of absence effective immediately" May 4 with no return date stated; Interim CFO appointed at $20K/month. $4.83M Q1 stock-based comp (20x prior year). Larvotto position $37M, marked down $4.1M.

What the market thinks

Analyst consensus $12.67 mean target, 4 Buys, 0 Sells. Options market reads bullish-skewed: P/C OI 0.13 (calls 7.9x puts), $12 strike has most call OI, ATM IV 117% in the 41st percentile (cheap). Heavy short interest 20.6%, 2.5 days to cover. January 2027 put deltas imply 26% probability stock <$7.50, 14% probability <$5.00.

Compute the gap

A scenario-weighted target (270d, blended across four states of the platform-execution thesis) lands at $9.74 undiscounted / $9.38 PV. Sharpe ≈ 0.39 — modest. Analyst consensus implicitly weights the bull case at ≈80%; we weight it at 30%, with 45% modal "incremental progress," 20% execution stress, 5% tail breakdown.

Market-implied P(>$12 by 61d) extracted from $12 call delta ≈ 30%. That matches our bull-tail estimate. The edge lives on the LEFT side of the distribution, not the right. Market over-prices the mild-stress region (≈$7.50) by ≈6pp and the tail-breakdown region (<$5) by ≈9pp. The bull case is partially priced by sophisticated call buyers; the modal incremental state is what we're paid for.

Why the gap exists

Small-cap with thin analyst coverage (Wainwright, B. Riley, William Blair, D. Boral). The disclosure sat in the MD&A liquidity section — the lowest-read part of a 10-Q. CEO Evans's Q4 2025 call language ("filings going out daily") was treated as boilerplate; this filing quantified it. USAR disclosed an analogous $1.58B LOI pipeline on the same filing day, but across nine US-listed critical minerals 10-Qs reviewed, only UAMY and USAR fit the "applying cohort" pattern (22% rate). Antimony has no ETF — the price tape is invisible to systematic flows. Rotterdam spot moved $49 → $51.80/kg between March and May while UAMY traded -19% on the week into the print.

Risks (ranked by impact)

1. $274M application conversion uncertainty. No assurance language; agency mix unknown beyond the $95M JV hydromet DoW filing. DoW DPA Title III application-to-award base rate is unknown.
2. CFO Isaak permanent departure. "Personal leave, effective immediately" is the standard pre-resignation framing. Pre-existing material weakness in disclosure controls would worsen. Sector peer ALM CFO also departed the same week.
3. Antimony price reversion. Rotterdam ≈2.4x pre-crisis. Demand destruction at sticker shock + downstream substitution (ZHS, Firebrake) + Larvotto Hillgrove mid-2026 production all argue against persistence.
4. Larvotto exposure. $37M in illiquid ASX small-cap, 10% holder, quarterly mark-to-market volatility. Failed Oct 2025 takeover at A$1.40 means strategic option constrained by Larvotto's board.
5. Dilution. $4.83M quarterly SBC at $8.30 grant prices, $48.6M ATM completed. Share count +9.3M dilutive plus warrant overhang.

Catalysts

• Aug 14, 2026 — Q2 earnings + Thompson Falls completion check
• Sept-Oct 2026 — First-window for additional federal award (typical 6-12mo from Q1 application filings)
• Nov 27, 2026 — China antimony export suspension expires; UAMY industrial customer 5-yr contract end-date matches exactly
• Dec 2026 — Rotterdam antimony print
• Q1 2027 — JV groundbreaking decision; CFO leave 8mo+ — permanent/return resolution

What would change our mind

Bullish: First federal award ≥$10M from the $274M stack confirms pipeline conversion. CEO Evans makes another open-market purchase (last buy Sept 2025 at $6.13). Larvotto Hillgrove on-time mid-2026 production confirmed.

Bearish: CFO permanent 8-K with no bench depth. SEC subpoena or restatement. $274M referenced as withdrawn in any IR communication. China extends antimony suspension unconditionally. Rotterdam breaks <$35/kg before December.

Evidence